跳至主要内容
临床试验/JPRN-UMIN000004691
JPRN-UMIN000004691已完成2 期

A phase 2 study of combination chemotherapy for hepatocellular carcinoma using Miripla (SM11355) and IA-call (DDP-H) - Combination chemotherapy of SM11355 and DDP-H for HCC

iigata Hepatocellular Carcinoma Therapy Study Group0 个研究点目标入组 200 人开始时间: 2011年9月18日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Pleural effusion and/or ascites refractory to treatments. 2) Comorbidity: >Active infectious diseases except for hepatitis. >Active bleeding from GI tract. >Active concomitant cancer with invasive nature. >Severe mental disorder or hepatic encephalopathy. 3) A history of severe allergic reaction against iodine contrast medium and/or platinum agents. 4) A pregnant or lactating female or female of childbearing age unless using effective contraception. 5) Ongoing interferon therapy. 6) Difficulties of oral intake. 7) Other serious conditions judged to be inadequate by a responsible doctor.

研究者

发起方
iigata Hepatocellular Carcinoma Therapy Study Group

相似试验